{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'PFS1 (PFS for SVdX patients only), defined as the duration of time from date of first', 'dose of SVd treatment after crossover from the Vd Arm until the first date of PD, or', 'death due to any cause', 'TTNT, defined as duration of time from date of last dose of study treatment until the', 'date of first dose of post-SVd/Vd/SVdX/SdX treatment', 'TTR, defined as duration of time from randomization until the date of first', 'documented response (>PR) per IMWG response criteria', 'PFS2 (PFS for patients who receive post-SVd/Vd/SVdX treatment), defined as the', 'duration of time from the date of first dose of post-SVd/Vd/SVdX treatment until the', 'first date of PD on post SVd/Vd/SVdX treatment, or death due to any cause', '5.2.3.', 'Secondary Safety Enppoints', '5.2.3.1.', 'Key Secondary Safety Endpoint', 'Incidence of any Grade >2 peripheral neuropathy events in patients randomized to the', 'SVd Arm versus patients randomized to the Vd Arm. The incidence of any Grade >2', 'peripheral neuropathy events will be compared between the SVd Arm and the Vd', 'Arm (using only events that occurred prior to crossover) as a secondary endpoint', 'using the safety population.', '5.2.3.2.', 'Non-Key Secondary Safety Enppoints', 'Safety and tolerability of study treatment based on AE reports, physical examination', 'results (including vital signs), Eastern Cooperative Oncology Group (ECOG)', 'performance status score, 12-lead electrocardiogram (ECG) results, ophthalmic', 'examination results, and clinical laboratory results', '5.2.4.', 'Secondary HR-QoL Endpoint', 'Patient-reported peripheral neuropathy, as measured by the EORTC-QLQ-CIPN20', 'instrument', '5.2.5.', 'Exploratory Endpoints', 'CCI', '5.2.6.', 'PK Enppoints', 'Bortezomib and selinexor PK parameters may include, but are not limited to,', 'estimations of maximum plasma concentration (Cmax), area under the concentration', 'versus time curve (AUC), and time to peak plasma concentration (tmax).', 'Confidential', 'Page 46', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '6.', 'INVESTIGATIONAL PLAN', '6.1.', 'Overall Study Design and Plan', 'This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study', 'will compare the efficacy and HR-QoL and assess the safety of selinexor plus bortezomib', '(Velcade or generic equivalent) plus low-dose dexamethasone (SVd) versus bortezomib', 'plus low-dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3', 'prior anti-MM regimens.', 'The study overview is presented in Figure 1.', 'Approximately 364 patients will be randomized from up to 120 global investigative sites.', 'Patients will be randomized to 1 of 2 treatment arms (SVd or Vd) in a 1:1 allocation, as follows:', 'SVd Arm (~182 patients): selinexor + bortezomib (QW) + dexamethasone', 'Vd Arm (~182 patients): bortezomib (BIW)+ dexamethasone', 'Randomization (Section 8.2) will be stratified based on:', 'Prior PI therapies (Yes or No)', 'Number of prior anti-MM regimens (1 versus >1)', 'R-ISS stage at study entry, based on screening results (R-ISS Stage III versus R-ISS', 'Stage I or II) (Palumbo 2015). If data for chromosomal abnormalities (CA) and serum', 'lactate dehydrogenase (LDH) required for R-ISS staging are not available, patients', 'will be assigned to the R-ISS category corresponding to their ISS stage.', 'It is planned to randomize patients within individual countries in a 1:1 allocation to SVd:Vd.', 'The number of patients enrolled may be adjusted based on the results of the interim analysis (IA)', 'for sample size re-estimation (first IA).', 'Patients in the Vd Arm who have PD that is confirmed by the IRC will be allowed to cross over', 'to a regimen that includes selinexor: 1) SVd treatment (SVdX) for patients who are able to', 'tolerate continued bortezomib, or 2) SdX for patients who have significant tolerability issues', 'with bortezomib, following the process described in Section 6.2. Patients who cross over will be', 'referred to as SVdX patients or SdX patients, respectively (Section 6.2).', 'The Schedule of Assessments is provided in Table 2. Patients will have in-clinic visits for dosing', 'of study treatment during MM evaluations (Table 13) and telephone contacts (Section 11.7.3).', 'Confidential', 'Page 47', 'Version 4.0']\n\n###\n\n", "completion": "END"}